New effective drug for Cushing's syndrome
Strongbridge Biopharma has announced the success of a new experimental drug against the rare Cushing's syndrome.
The pivotal LOGICS study has confirmed the potential of Recorlev (levoketoconazole) as an effective and well-tolerated inhibitor of cortisol synthesis for the treatment of Cushing's syndrome. This data, combined with previously published positive results from the Phase 3 SONICS trial, is believed to support the drug's US registration application, which is planned to be submitted to the FDA in the first quarter of 2021, according to Strongbridge Biopharma press release. The company has noted that levoketoconazole was well tolerated, but some adverse events, such as nausea (29%), headache (28%), hypokalemia (28%), diarrhea (15%) and hypertension (19%) were reported.